期刊文献+

腺病毒载体介导的CD基因转移联合5-FC对大鼠卵巢癌细胞株的作用研究 被引量:1

Gene Therapy for Ovarian Cancer by Adenovirus-mediated Transduction of Cytosine Deaminase Gene in vitro
下载PDF
导出
摘要 目的 研究胞嘧啶脱氨酶 (CD)基因转移及其与 5 -氟胞嘧啶 (5 - FC)联合应用对卵巢癌细胞株生长的影响。方法 用复制缺陷型重组腺病毒为载体 ,将 CD基因转染大鼠卵巢癌细胞株 NU TU - 19细胞 ,加入含 5 - FC的培养液培养。 MTT法检测培养孔吸光度值 ,计算细胞存活率。结果  5 - FC对转染了 CD基因的 NU TU - 19细胞的生长抑制作用显著增强 ,并随着腺病毒滴度和 5 - FC浓度的增加 ,该作用不断增强。此外 ,5 - FC可通过旁观者效应杀伤 CD基因转染细胞周围未转入该基因的 NU TU - 19细胞。结论  CD基因转移联合 5 - FC作用对 NUTU- Objective To study the value of adenovirus mediated expression of the Escherichia coli cytosine deaminase (CD) gene with 5 fluorocytosine (5 FC) in the gene therapy of ovarian cancer cells. Methods Ovarian cancer cells were transduced CD gene by adenovirus vector and exposed to varying concentration of 5 FC. After 5 days of incubation, MTT assays were performed to measure the cell viability. Results It was shown that tumor cells transduced with CD gene had a high sensitivity to 5 FC. Mixed cellular assay revealed that CD postive cells had a neighbor cell killing effect on CD negative cells when exposed to 5 FC. 20% CD positive cells killed more than 80% mixed cells. Conclusion CD/5 FC gene therapy approach is an effective anti tumor strategy in the treatment of ovarian cancer.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2003年第1期5-8,共4页 Journal of Sichuan University(Medical Sciences)
基金 国家自然科学基金资助 (批准号 3 9770 770 )
关键词 卵巢癌 基因治疗 胞嘧啶脱氨酶 5-氟胞嘧啶 Ovarian cancer Gene therapy Cystosine deaminase 5 Fluorocystosine
  • 相关文献

参考文献9

  • 1Mullen CA.Metabolic suicide genes in gene therapy[].Pharmacology and Therapeutics.1994
  • 2Ichikawa T,Tamiya T,Adachi Y,et al.I n vivo efficacy and toxicity of 5-fluorocytosine cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus[].Cancer Gene Therapy.2000
  • 3Kanai F,Lan KH,Shiratori Y,et al.I n vivo gene therapy for Fetoprotein-producing hepato-cellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene[].Cancer Research.1997
  • 4Miller R,Curiel DT.Towards the use of replicative adenovirus vectors for cancer gene therapy[].Gene Therapy.1996
  • 5Boucher PD,Ruch RJ,Shewach DS.Differential ganciclovirmediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase[].Human Gene Therapy.1998
  • 6Lan KH,Kanai F,Shiratori Y,et al.I n vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma[].Cancer Research.1997
  • 7Garcia-Sanchez F,Pizzorno G,Fu SQ,et al.Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologus trans-plantation[].Blood.1998
  • 8Huber BE,Austin EA,Richards CA,et al.Metabolism of 5fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase[].Proceedings of the National Academy of Sciences of the United States of America.1994
  • 9Huber BE,Richards CA,Austin EA,et al.Virus-directed enzyme prodrug therapy ( VDEPT )-selectively engineering drug sensitivity into tumors[].Annals of the New York Academy of Sciences.1994

同被引文献12

  • 1Koga S,Hirohata S,Kondo Y,et al.A novel telomerase-specific gene therapy:gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter[J].Hum Gene Ther,2000,11(10):1397 -1406.
  • 2Komata T,Kondo Y,Kanzawa T,et al.Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells[J].Hum Gene Ther,2002,13(9):1015 -1025.
  • 3Komata T,Koga S,Hirohata S,et al.A novel treatment of human malignant gliomas in vitro and in vivo:FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter[J].Int Oncol,2001,19 (5):1015 -1020.
  • 4Lin T,Huang X,Gu J,Zhang L,etal.Longterm tumor -free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells[J].Oncogene,2002,21 (52):8020-8028.
  • 5Liu J,Zou WG,Lang MF,etal.Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter[J].Int Oncol,2002,21(3):661 -666.
  • 6Majumdar AS,Hughes DE,Lichtsteiner SP,et al.The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters[J].Gene Ther,2001,8(7):568-578.
  • 7Braunstein I,Cohen-Barak O,Shachaf C,et al.Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells[J].Cancer Res,2001,61 (14):5529-5536.
  • 8Gu J,Kagawa S,Takakura M,et al.Tumorspecific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers[J].Cancer Res,2000,60 (19):5359-5364.
  • 9Koga S,Hirohata S,Kondo Y,et al.FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo[J].Anticancer Res,2001,21 (3B):1937-1943.
  • 10Komata T,Kondo Y,Kanzawa T,et al.Treatment of malignant glioma cells with the transfer of constitutively active caspase -6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter[J].Cancer Res,2001,61 (15):5796 -5802.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部